Journal of Clinical Psychopharmacology最新文献_第2页

Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap. 抗精神病药物的时间过程：交叉滴定陷阱的证据。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-10-19 DOI: 10.1097/JCP.0000000000001916

Marc W H Lochmann van Bennekom, Harm J Gijsman, Joanna IntHout, Robbert Jan Verkes

{"title":"Antipsychotic Polypharmacy in Time Course: Evidence for a Cross-titration Trap.","authors":"Marc W H Lochmann van Bennekom, Harm J Gijsman, Joanna IntHout, Robbert Jan Verkes","doi":"10.1097/JCP.0000000000001916","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001916","url":null,"abstract":"Purpose/background: Antipsychotic polypharmacy (APP) is controversial yet applied in 20% of patients with psychotic disorders. We investigated indications for initiating and continuing APP, including the contribution of unfinished cross-titrations.Methods/procedures: This 2-month study was part of a prospective study to reduce inappropriate APP in inpatients. With each new prescription resulting in APP, we asked the prescriber for the indication (eg, switching antipsychotics, sedation for agitation/sleep disorders, treatment refractoriness, other) and repeated this at 30 and 60 days. Secondary outcome was unfinished cross-titration at 60 days.Findings/results: In a consecutive cohort of 55 patients, 80% diagnosed with schizophrenia, switching antipsychotics was the primary initial indication for APP in 31 of 55 patients (56%), followed by sedation in 12 of 55 patients (22%), and treatment refractoriness in 10 of 55 patients (18%). Overall, APP was discontinued after 30 days in 25 of 55 patients (45%) and after 60 days in 28 of 55 patients (51%). At 60 days, APP initiated for switching antipsychotics was ongoing in 9 of 31 patients (29%), APP initiated for sedation was ongoing in 8 of 12 patients (66%), and APP initiated for refractoriness was ongoing in 9 of 10 patients (90%). The initial indication for APP was maintained at 60 days in 21 of 27 patients (78%). Unfinished cross-titration occurred in 9 of 31 patients (29%) with APP initiated for switching antipsychotics.Implications/conclusions: APP was initiated primarily because of cross-titration switching of antipsychotics. The reason for APP was generally maintained consistently over time, particularly when initiated for treatment refractoriness. Of all patients with APP initiated to switch antipsychotics, 29% ended in unfinished cross-titration.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suicidal Ideation and Self-harming Thoughts With Valbenazine Use: A Case Report. 使用戊苯那嗪后出现自杀念头和自残想法：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-10-16 DOI: 10.1097/JCP.0000000000001920

Jake Neeman, Shelby E Lang, Jianwei Jiao

引用次数: 0

Health Alert: Microdose Products Leading to Acute Illness and Hospitalizations Across the United States. 健康警报：微剂量产品在全美导致急性疾病和住院治疗。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-17 DOI: 10.1097/JCP.0000000000001919

Elisa Nguyen, Abraham Qavi, Minh-Ha Tran

引用次数: 0

Mechanisms of Drug-Associated Burning Mouth Syndrome. 药物相关灼口综合征的机理。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-11 DOI: 10.1097/jcp.0000000000001915

Takahiko Nagamine

引用次数: 0

A Case Series: Psychotic Disorder Associated With Gummies Containing Delta-8-Tetrahydrocannabinol. 病例系列：与含有δ-8-四氢大麻酚的软糖有关的精神紊乱。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001884

David R Spiegel, Jason Bard, Megan Ralston, William Crafton, Alim Osman, Kallen Hager, Pavan Suryadevara

引用次数: 0

Modafinil Use in an Adolescent With Major Depressive Disorder. 青少年重度抑郁症患者使用莫达非尼。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001893

Ecem Özer Çakır, Oğuz Bilal Karakuş, İbrahim Adak

引用次数: 0

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1097/JCP.0000000000001886

Reza Rafizadeh, Ataa Azarbar, Lukas Hestvik, Jennifer Clune, Nickie Mathew

引用次数: 0

High-Dose Propranolol for Severe and Chronic Aggression in Autism Spectrum Disorder: A Pilot, Double-Blind, Placebo-Controlled, Randomized Crossover Study. 大剂量普萘洛尔治疗自闭症谱系障碍患者的严重和慢性攻击行为：一项试验性、双盲、安慰剂对照、随机交叉研究。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-23 DOI: 10.1097/JCP.0000000000001895

Eric B London, Barbie L Zimmerman-Bier, J Helen Yoo, Joseph W Gaffney

{"title":"High-Dose Propranolol for Severe and Chronic Aggression in Autism Spectrum Disorder: A Pilot, Double-Blind, Placebo-Controlled, Randomized Crossover Study.","authors":"Eric B London, Barbie L Zimmerman-Bier, J Helen Yoo, Joseph W Gaffney","doi":"10.1097/JCP.0000000000001895","DOIUrl":"10.1097/JCP.0000000000001895","url":null,"abstract":"Background: Despite the use of behavioral interventions and psychotropic medications, many individuals with autism spectrum disorder (ASD) who engage in severe aggression remain refractory to conventional treatment. Propranolol, a beta-blocker, has accumulated much anecdotal evidence as a promising option. However, well-designed studies are rare, and the apprehension about cardiovascular side effects from large doses continues to exist.Purpose: The aims of this study were (1) to demonstrate the feasibility of treating aggression with high-dose propranolol using telehealth study visits and (2) to document cardiac safety.Methods: This study utilized a randomized, double-blind, placebo-controlled, crossover design. Dosing was titrated up in a flexible but stepwise fashion until therapeutic response was obtained or up to 200 mg tid. Following washout, those who were assigned propranolol were crossed over to placebo and vice versa. Six participants between the ages 12-19 participated. The primary outcome measures were the final Clinical Global Impression Improvement Scale (CGI-I) and the Aberrant Behavior Checklist-Community Irritability (ABC-C/I) scores at 200 mg tid.Results: The CGI-I indicated a 50% reduction in symptoms in the propranolol phase, while the ABC-I indicated a 37% reduction in comparison to placebo. The effect sizes ( r ) for the CGI-I and the ABC-C/I were large, -0.74 and -0.64, respectively. The average blood pressure was 122/68 during the placebo phase and 109/72 during the propranolol phase. All Holter monitor exams were unremarkable.Conclusion: These results suggest that propranolol is an effective option in decreasing aggression in individuals with ASD. As this was a small study, a larger clinical trial is needed.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"462-467"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case Report and Mini Review on Clozapine Treatment During Chemotherapy: Is it Possible to Manage Neutropenia Successfully With Secondary G-CSF? 关于化疗期间氯氮平治疗的病例报告和小型综述：二次 G-CSF 能否成功控制中性粒细胞减少症？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1097/JCP.0000000000001900

Selvi Ceran, Beren Özel, Ali Ercan Altinoz, Nurhak Çağatay Birer, Arzu Oğuz

引用次数: 0

Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial. 阿戈美拉汀在健康志愿者社交焦虑模型中缺乏急性效应：双盲、安慰剂对照试验。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001888

Rafael G Dos Santos, Isabella C da Silva Dias, Antonio W Zuardi, Regina H C Queiroz, Francisco S Guimarães, Jaime E C Hallak, José Alexandre S Crippa

{"title":"Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial.","authors":"Rafael G Dos Santos, Isabella C da Silva Dias, Antonio W Zuardi, Regina H C Queiroz, Francisco S Guimarães, Jaime E C Hallak, José Alexandre S Crippa","doi":"10.1097/JCP.0000000000001888","DOIUrl":"10.1097/JCP.0000000000001888","url":null,"abstract":"Background: Agomelatine is an antidepressant drug that acts as an agonist of melatoninergic MT1/2 receptors and an antagonist of serotonergic 5-HT2C receptors. Studies suggest that agomelatine has anxiolytic properties in social anxiety, but there are no studies that assessed the effects of this compound in human experimental anxiety induced by a public speaking test. The objective of our investigation was to assess the effects of agomelatine on human experimental anxiety using the Simulation Public Speaking Test (SPST).Methods: Agomelatine (25 mg, n = 14), citalopram (20 mg, n = 14), venlafaxine (75 mg, n = 14), or placebo (n = 14) were administered in single doses to healthy volunteers in a double-blind study. Subjective anxiety was assessed with the Visual Analogue Mood Scale. Arterial blood pressure, heart rate, and blood levels of prolactin and cortisol were also recorded, as well as plasma levels of the 3 drugs.Results: The SPST induced significant subjective, physiological, and hormonal effects in all groups. The SPST also increased the anxiety and decreased mental sedation Visual Analogue Mood Scale factors during the anticipatory and performance phases of the test. Citalopram increased anxiety during the test in females, whereas agomelatine and venlafaxine were not different from placebo.Conclusions: Confirming previous results, a serotonin selective reuptake inhibitor, citalopram, caused an anxiogenic effect in the SPST only in females. Acute administration of a low dose of agomelatine failed to modify the behavioral and physiological changes caused by this test. Future studies using higher doses and repeated administration should investigate if agomelatine behavioral and physiological effects could be detected in human experimental anxiety models.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"472-480"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0